Cite
HARVARD Citation
James, N. et al. (2022). Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. BJUI Compass. 3 (6), pp. 484-493. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
James, N. et al. (2022). Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. BJUI Compass. 3 (6), pp. 484-493. [Online].